High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24)

Leukemia (2013) 27, 980–982; doi:10.1038/leu.2012.266

In a previous publication of ours, we showed the involvement of the myeloid translocation gene-related protein 2 gene (CBFA2T3) in a case of acute erythroid leukemia with the t(1;16)(p31;q24). Because of lack of material available for analysis, we could not with certainty determine the leukemogenic mechanism, whether it be generation of a fusion gene with CBFA2T3 as one of the partners or loss of tumor suppressor activity, in which case genes KANK1 and L1TD1, both homozgyously lost, might be of the essence.

Some months after our article was published we got hold of 2 ml coagulated blood with 3% of abnormal cells from the same patient. As sequencing technology has also developed very fast lately, we decided to extract RNA from the sample and try to use it for high-throughput sequence analysis. The RNA was extracted and its quality checked by the Experion automated electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). A total of 3 µg of RNA was sent for high-throughput pair-end RNA-sequencing to the Norwegian Sequencing Center at the Ullevål Hospital (http://www.sequencing.uio.no/). The Illumina software pipeline was used to process image data into raw sequencing data and only sequence reads marked as ‘passed filtering’ were used in the downstream data analysis. A total of 107 million reads were obtained. The FASTQC software was used for quality control of the raw sequence data (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). We used the fusion discovery software FusionMap (release date 16-04-2012) and the pre-built Human B37 and RefGene from the FusionMap website (http://www.omicsoft.com/fusionmap/). A list of over 500 possible fusion genes was obtained.

A specific fusion involving the CBFA2T3 gene, which maps to chromosome band 16q24, and the nuclear factor I/A (NFIA) gene, which maps to chromosome band 1p31, was identified as number 10 in the list (seed count-rank 48; Supplementary Table 1). The involvement of the NFIA gene fits well with the fluorescence in situ hybridization (FISH) data on chromosome 1 previously obtained and published. The presence of the NFIA/CBFA2T3 fusion was verified by PCR using the NFIA-956 F and CBFA2T3-622 R primer combination (Supplementary Table 2). A specific PCR product of about 500 bp was identified and directly sequenced (Figure 1a). The specific fusion occurs between exon 6 of the NFIA gene (accession number NM_001134673.3) and exon 3 of the CBFA2T3 gene (accession number NM_005187.5; Figure 1b).

The NFIA/CBFA2T3 fusion gave an open reading frame and is expected to lead to a chimeric protein containing 208 amino-acid residues from NFIA (according to NP_001128145.1) and 603 residues from CBFA2T3 (according to NP_005178.4). The predicted fusion protein should thus consist of 811 amino acids (Figure 1c).

The NFIA gene encodes a member of the NFI family of transcription factors (http://genome.ucsc.edu). Interestingly, it has been found that NFIA exhibits a marked lineage-specific expression pattern in normal human hematopoiesis; it is upregulated in the erythroid lineage but fully suppressed in granulocytopoiesis. It has been shown that in early hematopoiesis, the NFIA expression level acts as a factor channeling hematopoietic progenitor cells into either the erythroid or granulocytopoietic lineage. The NFI proteins have a DNA-binding and dimerization domain in their N-terminal half, which contains four cysteine residues, and a transactivation and repression domain in their C-terminal half. The NFIA gene was found involved in an NFIA/EHF chimeric fusion in one breast cancer cell line out of 24 breast tumors analyzed (nine cell lines and 15 primary tumors). However, its role as either a passenger event or a direct, albeit infrequent, contributor to breast cancer development remains uncertain.

CBFA2T3 encodes an ETO myeloid translocation gene family protein, which interacts with DNA-bound transcription factors and recruits a variety of corepressors to facilitate transcriptional repression. The t(16;21)(q24;q22) translocation is one of the less common karyotypic abnormalities specifically associated with acute myeloid leukemia (AML). The translocation produces a chimeric gene made up of the 5’-region of the runt-related transcription factor 1 (RUNX1) gene fused to the 3’-region of CBFA2T3 (Figure 1d). In AMLs with either t(8;21) or t(16;21), the transcription factor RUNX1 is juxtaposed to one of the zinc finger nuclear proteins CBFA2T1 and CBFA2T3, respectively, resulting in transcriptional repression of RUNX1 target genes. Lately, its involvement as a partner in fusion genes was underlined by the identification of a IGH/CBFA2T3 fusion in a case of Burkitt lymphoma and a diffuse large B-cell lymphoma. This gene is also a putative breast tumor suppressor. Interestingly, CBFA2T3 is downregulated during erythroid differentiation, and it has been...
suggested to have a repressive role in early, as well as late human erythroid differentiation. Hildebrand et al. demonstrated that the nuclear protein ETO (eight-twenty-one, a family to which also CBFA2T1, CBFA2T2 and CBFA2T3 belong) does not show reduced repressor activity even if it lacks the first 236 amino acids. As in the present fusion the altered CBFA2T3 protein lacks only the first 50 amino acids, we assume that its repressor activity is still retained (Figure 1e). More specifically, we hypothesize a pathogenetic parallel between AML showing a t(8;21) or t(16;21) and the present erythroleukemia with the 1;16-translocation with transcriptional repression of the NFIA target genes in the present case.

As the karyotype was described as 46,XY,der(1)t(1;1)(p31;q21),-del(1)(p11p31),der(16)t(1;16)(p31;q24), that is, presented additional rearrangement besides the 1;16-translocation, we decided to screen the list of possible fusion genes in search of genes located in karyotypic breakpoints to see if those were involved in fusions as well. We identified four possible fusions (seed count-rank >12) where one of the genes mapped to a breakpoint position on chromosome 1. An analysis of the hypothetical fusions using the BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) showed in one of the two genes high-sequence identity with several genes and/or numerous repetitive sequences (for example, SINE). Hence, the reality of the putative fusions was seriously called into question and no further investigations were undertaken.

In addition to the present case, two more cases of erythroleukemia showing a t(1;16)(p31;q24) in their karyotype can be found in the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. All three patients (including ours) were very young children, and clinical outcome was poor. We assume that a NFIA/CBFA2T3 fusion existed also in these leukemias, but no evidence is at hand to corroborate or falsify this assumption.

In summary, we describe the first fusion gene identified in acute erythroleukemia. Knowledge of its specific functions in the neoplastic context is still incomplete, but pathogenetic similarities with other leukemic fusion genes are readily discernible. As for other leukemias characterized genetically by fusion genes, one may assume that the detailed pathogenetic knowledge now emerging may eventually form a starting point from which therapeutic attempts may begin.

Figure 1. Detection of the NFIA/CBFA2T3 fusion. (a) Gel picture showing the amplified fragment. Lane 1: ladder, lane 2: PCR product obtained with primer combination NFIA-924 F and CBFA2T3–622 R, lane 3: product of the NESTED-PCR obtained with primer combination NFIA-956 F and CBFA2T3–598 R. (b) Partial chromatogram showing the junction of the NFIA and CBFA2T3 genes. (c) Deduced amino acid sequence of the fusion transcript. (d) Schematic overview of the breakpoint region of the NFIA and CBFA2T3 genes. The exons are not in scale. Arrows point to primer positions. (e) Schematic overview of the position of the different domains of the NFIA and CBFA2T3 proteins and the NFIA/CBFA2T3 chimeric protein, according to ensembl (http://www.ensembl.org/index.html).
CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This study was approved by the Regional Ethics Committee (REK number: S-07474a) and the institutional review board. The study was supported by grants from the Norwegian Cancer Society and the South-Eastern Norway Regional Health Authority. The sequencing service was provided by the Norwegian High-Throughput Sequencing Center, a national technology platform supported by the ‘Functional Genomics’ and ‘Infrastructure’ programs of the Research Council of Norway and the South-Eastern Regional Health Authorities.

F Micci1,2, J Thorsen1,2, I Panagopoulos1,2, KB Nyquist1,2, B Zeller3, A Tierens4 and S Heim1,2,5
1Section for Cancer Cytogenetics, Institute for Medical Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway;
2Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway;
3Department of Pediatrics, Rikshospitalet, Oslo University Hospital, Oslo, Norway;
4Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway and
5Faculty of Medicine, University of Oslo, Oslo, Norway E-mail: francesca.micci@labmed.uio.no

REFERENCES
1 Micci F, Thorsen J, Haugom L, Zeller B, Tiersen A, Heim S et al. Translocation t(1;16)(p31;q24) rearranging CBFA2T3 is specific for acute erythroid leukemia. Leukemia 2011; 25: 1510–1512.
2 Ge H, Liu K, Juan T, Fang F, Newman M, Hoeck W. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 2011; 27: 1922–1928.
3 Stennes LM, Sorrentino A, Pelosi E, Ballarino M, Marsili O, Biffoni M et al. NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood 2009; 114: 1753–1763.

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases

Leukemia (2013) 27, 982–985; doi:10.1038/leu.2012.267

Therapy-related myeloid neoplasms (t-MN), including acute myeloid leukemias (t-AML) and myelodysplastic syndromes (t-MDS), indicate myeloid disorders developing in patients treated with radiotherapy and/or chemotherapy for cancer or autoimmune diseases. t-MN represent a unique model of in vivo poison-induced leukemogenesis. It displays a high incidence of monosomies, complex karyotypes and p53 mutations, but other AML-associated mutations, as FLT3, NPM1, CEBPA and TET2 (ten-eleven-translocation 2), are usually rare.1–3 In addition, t-MN have been shown to display significant changes in gene expression, including upregulation or downregulation of pathways involved in major cellular processes, which are present long before the development of the t-MN and may be expression of early progenitor damage.4 These changes are due to the synergistic negative effects of previous treatments, probably in the presence of individual predisposing factors, and finally result into leukemic transformation.

Epigenetic deregulation of gene expression is one of the main pathogenetic processes in AML and MDS. High rates of gene-specific methylation have been reported in these diseases,5–7 but the underlying mechanisms are poorly understood. The identification of mutations in several genes involved in epigenetic regulation has given new insights. Among these, recurrent somatic mutations of enzymes involved in methylation, including DNMT3A (DNA methyltransferase 3A), IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2), TET2 and EZH2 (enhancer of